Heerlen, NL, 27 Oct 2011 09:15 CEST
Royal DSM, the global Life Sciences and Materials Sciences company, today announces it has sold a majority shareholding in TCG B.V. to MocoLabs, Inc. DSM will remain involved in TCG as a minority shareholder through DSM Venturing. Financial details of the transaction will not be disclosed.
TCG was part of DSM’s Emerging Business Area Specialty Packaging in the Innovation Center. As announced in September 2010, the focus was moved to other EBA’s and Specialty Packaging activities were to be partnered, exited or transferred to other parts of DSM. TCG develops and markets e-communicative packaging solutions that help people manage their own health. TCG has developed and patented the OtCM™ system which measures and monitors patient therapy compliance while interacting wirelessly with home diagnostic devices to correlate compliance with drug therapy.
Rob van Leen, DSM’s Chief Innovation Officer, said: "I am pleased to announce this agreement with MocoLabs, as their vision with respect to the patient compliance market is very appealing. We believe MocoLabs is the right partner to make this business a success. It has the network, the market knowledge and a time-to-market focus to capture this fast-growing market opportunity and DSM will be able to capitalize on that as a minority shareholder."
Bjorn Janse, CEO of MocoLabs, Inc., adds: "We are proud of the trust that DSM has placed in us and are delighted that we both share the same vision on the future strategy of these Specialty Packaging Pharma activities. With DSM as a partner we will enter the market with a strong focus on supporting consumers to improve their quality of life by e-communicative packaging, as well as by sophisticated positive enforcement systems.”
TCG B.V. has changed its name to Qolpac B.V., which is short for 'Quality of life improving packaging' and has moved from Urmond to Enschede, the Netherlands. Qolpac has created two programs: HealtheNess and OtCM™. Whereas the HealtheNess program has its focus in the consumer and retail branch, OtCM™ will focus more on the pharma industry as well as the clinical research organizations.